The Effect of β-Blocker Use on Cyclosporine Level in Cardiac Transplant Recipients

This publication has 15 references indexed in Scilit:

• Carvedilol: a new candidate for reversal of MDR1/P-glycoprotein-mediated multidrug resistance
  Anti-Cancer Drugs, 2004
• Role of Angiotensin II and Reactive Oxygen Species in Cyclosporine A–Dependent Hypertension
  Hypertension, 2003
• Effects of carvedilol on MDR1 ‐mediated multidrug resistance: comparison with verapamil
  Cancer Science, 2003
• Cyclosporine A and control of vascular tone in the human forearm
  Journal Of Hypertension, 1999
• Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*
  Clinical Pharmacology & Therapeutics, 1997
• Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo correlation
  British Journal of Pharmacology, 1996
• Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
  Journal of Clinical Investigation, 1995
• Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
  Molecular Carcinogenesis, 1995
• Cyclosporine-Induced Sympathetic Activation and Hypertension after Heart Transplantation
  New England Journal of Medicine, 1990
• The contrasting effects of cyclosporin-A and azathioprine on arterial blood pressure and renal function following cardiac transplantation
  International Journal of Cardiology, 1986